A method of treating a subject presenting with multiple myeloma at a stage characterized by an increase in the prevalence of MM cells that (1) are IL-6 non-responsive and/or (2) have a CD45&minus； phenotype, comprising administering to the subject an amount of a compound of formula Ib.
